GLP-1 receptor agonist-based therapies significantly reduced major adverse limb events, amputations, need for revascularization, and mortality in patients with peripheral artery disease.
42% fewer amputationsGLP-1 drug users in the T2D cohort had dramatically fewer limb amputations
What the researchers found
In PAD patients: MALE OR 0.66 (p=0.05), revascularization OR 0.85 (p<0.001), mortality OR 0.55 (p=0.0008), MACE OR 0.68 (p=0.004). In T2D patients: MALE OR 0.70 (p=0.0005), amputations OR 0.58 (p<0.001).
Why it matters
PAD-related amputations devastate quality of life. A 42% reduction in amputations from GLP-1 drugs could save thousands of limbs annually.
How the study worked
Systematic review and meta-analysis of 10 PAD studies (352,743 patients) and 7 T2D studies (1,759,799 patients) evaluating GLP-1 RA-based therapies on limb and cardiovascular outcomes.
What this study cannot tell us
High heterogeneity in mortality analysis (I² up to 97%). Mix of observational and trial data. Cannot determine optimal GLP-1 drug or dose for PAD.
How to read the evidence
Systematic review and meta-analysis of 17 studies with over 2 million patients. High-quality evidence synthesis, though with significant heterogeneity.
When this study was published
Published in 2025.
The bigger picture
This adds peripheral vascular protection to the growing list of GLP-1 drug benefits, suggesting these peptide drugs protect blood vessels throughout the body.
Questions still open
- What vascular mechanisms explain GLP-1 drugs' limb-protective effects?
- Should GLP-1 drugs be standard care for all PAD patients, regardless of diabetes status?
- Can GLP-1 therapy prevent progression from early to critical limb ischemia?
Common questions
Can GLP-1 drugs save limbs in peripheral artery disease?
Should PAD patients take GLP-1 drugs?
Read the original research
Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.
Diabetes, obesity & metabolism, 28(3), 2075-2084
Citation
Dutta, Deep; Mahajan, Kunal; Kamrul-Hasan, Abul Bashar Mohammad; Mahajan, Nitin; Sharma, Meha; Vohra, Shekhar. (2026). Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.. Diabetes, obesity & metabolism, 28(3), 2075-2084. https://doi.org/10.1111/dom.70391